1)Kamisawa T, Wood LD, Itoi T, et al:Pancreatic cancer. Lancet 388:73-85, 2016
2)Wada K, Takaori K, Traverso LW, et al:Clinical importance of Familial Pancreatic Cancer Registry in Japan:a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci 20:557-566, 2013
3)Klein AP, Brune KA, Petersen GM, et al:Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638, 2004
4)Matsubayashi H, Maeda A, Kanemoto H, et al:Risk factors of familial pancreatic cancer in Japan:current smoking and recent onset of diabetes. Pancreas 40:974-978, 2011
5)Matsubayashi H, Takaori K, Morizane C, et al:Familial pancreatic cancer:Concept, management and issues. World J Gastroenterol 23:935-948, 2017
6)Giardiello FM, Brensinger JD, Tersmette AC, et al:Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447-1453, 2000
7)Roberts NJ, Jiao Y, Yu J, et al:ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41, 2012
8)Sakai D, Kanai M, Kobayashi S, et al:Randomized phase III study of gemcitabine, cisplatin plus S-1(GCS)versus gemcitabine, cisplatin(GC)for advanced biliary tract cancer(KHBO1401-MITSUBA). Ann Oncol 29(Suppl 8):viii205-viii270, 2018
9)Kondo T, Kanai M, Kou T, et al:Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 9:19817-19825, 2018
10)森実千種,北野雅之,肱岡 範,他:膵癌早期発見に向けた家族性膵癌登録.膵臓32:23-29,2017
11)Canto MI, Goggins M, Hruban RH, et al:Screening for early pancreatic neoplasia in high-risk individuals:a prospective controlled study. Clin Gastroenterol Hepatol 4:766-781, 2006
12)Canto MI, Harinck F, Hruban RH, et al:International Cancer of the Pancreas Screening(CAPS)Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339-347, 2013
13)北野雅之,森実千種,肱岡 範,他:家族性膵癌早期診断に向けたサーベイランス法(エキスパート・コンセンサス).膵臓2020(印刷中)